Upgrade to SI Premium - Free Trial

Morgan Stanley Downgrades Biogen (BIIB) to Equalweight

October 31, 2024 3:13 AM
Morgan Stanley analyst Terence Flynn downgraded Biogen (NASDAQ: BIIB) from Overweight to Equalweight with a price target of $204.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades

Next Articles